Omnicell Stock Price, News & Analysis (NASDAQ:OMCL)

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, July, 25th. The company reported $0.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.04. The company earned $217.40 million during the quarter, compared to analyst estimates of $214.13 million. Omnicell had a return on equity of 11.85% and a net margin of 5.70%. Omnicell's revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.46 earnings per share. View Omnicell's Earnings History.

Omnicell is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for Omnicell.

Omnicell will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Omnicell issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $2.65-$2.82 for the period, compared to the Thomson Reuters consensus estimate of $2.77. The company issued revenue guidance of $886-$900 million, compared to the consensus revenue estimate of $891.96 million.

7 Wall Street analysts have issued 12 month price targets for Omnicell's stock. Their forecasts range from $61.00 to $90.00. On average, they expect Omnicell's share price to reach $80.29 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for Omnicell.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.

Media coverage about OMCL stock has trended somewhat positive on Monday, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Omnicell earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Omnicell.

Some companies that are related to Omnicell include Cerner (CERN), Medidata Solutions (MDSO), HMS (HMSY), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA), Cortexyme (CRTX), Computer Programs & Systems (CPSI) and Greenway Health (GWAY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Micron Technology (MU), Paypal (PYPL), AbbVie (ABBV), Adobe (ADBE), Align Technology (ALGN), Netflix (NFLX) and NVIDIA (NVDA).

Omnicell's stock is owned by a number of of retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (0.80%), Tributary Capital Management LLC (0.65%), Peregrine Capital Management LLC (0.65%), Summit Creek Advisors LLC (0.53%), Scout Investments Inc. (0.44%) and Rhenman & Partners Asset Management AB (0.22%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Institutional Ownership Trends for Omnicell.

OMCL stock was sold by a variety of institutional investors in the last quarter, including Pwmco LLC, Strs Ohio, Scout Investments Inc., Calamos Advisors LLC, Rhenman & Partners Asset Management AB, Tributary Capital Management LLC, Stephens Investment Management Group LLC and CIBC Private Wealth Group LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View Insider Buying and Selling for Omnicell.

OMCL stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Summit Creek Advisors LLC, Bowling Portfolio Management LLC, State of Alaska Department of Revenue, Assenagon Asset Management S.A., Zurcher Kantonalbank Zurich Cantonalbank , Brinker Capital Inc. and Stephens Inc. AR. View Insider Buying and Selling for Omnicell.

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OMCL stock can currently be purchased for approximately $77.75.

Omnicell has a market capitalization of $3.24 billion and generates $787.31 million in revenue each year. The company earns $37.73 million in net income (profit) each year or $1.53 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.View Additional Information About Omnicell.

The official website for Omnicell is http://www.omnicell.com/.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]